-
Tunisia says 2026 summer hottest on record
-
Republican senator seeks probe of Trump Jr Russian-funded wedding
-
England's Rashid out of Sri Lanka ODIs with hand injury
-
Memoir by Diana's brother goes on sale after rocking UK monarchy
-
Houthis accuse Saudi Arabia of deadly strikes as thousands flee
-
Newcomers South Korea face holders Italy in Davis Cup finals
-
Stocks climb as oil slides, AI buzz returns
-
Japan's Kojima sounds Marchand warning with Asian Games gold
-
India cricketers win in style as Afghan savours 'special' Games silver
-
England rugby star Pollock signs new Northampton deal
-
La Liga president hits out at Real Madrid refereeing 'conspiracy' claims
-
STARTRADER Expands Its Chinese Equity CFD Range with CXMT and Unitree Robotics
-
MEXC Launches “Real Stocks, Real Friends” with Rewards for Bringing Friends to Wall Street
-
MEXC Expands Opportunity Compass with Stock Trading Handbook to Help Crypto Users Build Investment Knowledge
-
Mbappe continues media push for Ballon d'Or recognition
-
England paceman Wood retires from international cricket
-
Stocks rise on AI buzz, oil prices cool
-
Magnificent Mandhana's 79 helps India to Asian Games cricket gold
-
India narrowly survive huge scare against minnows Japan
-
Marchand 'stressed' about racing Japanese rivals at LA Olympics
-
Missing F-35 fighter parts 'not sensitive', says Australia minister
-
Mobile boat clinics bring healthcare to India's remote islands
-
Cambodia showcases scams crackdown with global conference
-
Former India paceman Zaheer Khan named Chennai coach in IPL
-
Afghan cyclist who disguised herself as man wins Asian Games silver
-
Six-year-old Chinese girl sets world record with Rubik's Cube
-
Typhoon Dujuan leaves four dead in Japan, 45,000 houses without power
-
Swimming prodigy Yu, 13, says 'interviews way harder than racing'
-
G7 leaders condemn Houthi strikes on Saudi Arabia
-
Star coaches make their bows as Nations League returns
-
Google data centre sparks protests in Austria
-
Rams bounce back as Giants reel from Dart injury
-
Shin Ohashi: Junk food-loving teen and Japan's next big swimming hope
-
In Bangladesh, Pakistan's Jinnah photo stirs anger
-
Stocks rise on AI buzz, drop in oil prices
-
Two New Zealand naval ships transit Taiwan Strait
-
China's robot dancers limber up for America's Got Talent final
-
Zidane gets down to work as France start new era
-
Despite military might, Saudi struggles to crush the Houthis
-
Inside the Venezuelan prison meant to 'drive you insane'
-
Trump to tout deals, defend Iran war in UN speech
-
UK king braces as memoir by Diana's brother goes on sale
-
Sri Lanka to issue verdict in landmark Easter attack trial
-
No green light to lift EU sanctions on Russian oligarchs, talks to resume
-
Macron says talks with Trump on Red Sea, Ukraine 'constructive'
-
UK agrees support for Saudi in struggle with Houthis: reports
-
Green policies just good politics, says UK minister
-
EU foreign policy chief calls for continued sanctions on Russia
-
Bardot auction in Paris fetches nearly one million euros
-
Flights scrapped, evacuations urged as Typhoon Dujuan wallops Japan
Court to hear lawsuit seeking to ban abortion pill in US
A Texas judge favored by anti-abortion activists will hear arguments Wednesday in an unprecedented challenge to the legality of a widely-used abortion pill.
US District Court Judge Matthew Kacsmaryk announced Monday the hearing on a lawsuit alleging the US Food and Drug Administration (FDA) should never have approved the "dangerous" prescription drug Mifepristone in 2000.
Mifepristone, one component of a two-drug regimen used for medication abortion, has been used by an estimated 5.6 million women to terminate pregnancies since its approval, according to the FDA.
It is can be used in the United States up to 10 weeks of pregnancy.
The pro-abortion rights Guttmacher Institute estimates that more than half of all abortions involve the use of mifepristone.
But the Alliance Defending Freedom, a Christian advocacy group, sued the FDA saying its approval "disavow(ed)" science, "ignored" potential health impacts and "disregarded" the complications that can arise with using mifepristone.
"The FDA failed America's women and girls when it chose politics over science and approved chemical abortion drugs for use in the United States," they said.
Galvanized by the Supreme Court's ruling in June that overturned the constitutional right to an abortion, abortion opponents have now set their sights on obtaining prohibitions on mifepristone.
Already the treatment has been halted in some 15 states which have banned all abortion since the 2022 Supreme Court decision.
The Texas suit seeks to block it nationally by overturning the FDA's approval of the drug.
The FDA has urged the judge to reject the request.
"The public interest would be dramatically harmed by effectively withdrawing from the marketplace a safe and effective drug that has lawfully been on the market for 22 years," it said.
Kacsmaryk was targeted by the plaintiffs to hear the case due to his deep conservative Christian beliefs and previous anti-abortion stance.
He had been expected since February 24 to issue a ruling in the case, which asks him to suspend the FDA's approval of the drug while the lawsuit proceeds.
Apparently fearing protestors descending on the courthouse in Amarillo, Texas, Kacsmaryk originally sought to keep the hearing secret until the last minute, but it leaked to media.
If he does order the suspension, it could leave pregnant women with the alternative of using only misoprostol, the second pill in the medication abortion treatment.
But using misoprostol alone is more physically traumatic than the two-pill procedure, and some fear doctors might be unwilling to prescribe it alone.
If mifepristone is banned, "access to medication abortion would end across the country -- even in those states where abortion rights are protected," the Center for Reproductive Rights said.
O.Bulka--BTB